Latest Strategy News

Empire Resources has reported promising preliminary assay results from its April 2026 RC drilling campaign at the Yuinmery Copper-Gold Project, revealing new copper and gold mineralisation across multiple prospects including the newly identified Hillside and Microbe Well zones.

Silver Mines has submitted a refreshed Biodiversity Development Assessment Report for its Bowdens Silver Project, moving the development application closer to redetermination by NSW authorities. The project remains a critical minerals priority with significant job creation potential.

Native Mineral Resources (ASX:NMR) has raised A$3.5 million through a convertible note with Lind Global Fund III LP, providing immediate working capital and flexibility for its growth plans.

Australis Oil and Gas has submitted a permit application for the first well under its US$46.25 million carried work program in the Tuscaloosa Marine Shale, targeting a Q4 2026 spud and expanding its held-by-production acreage.

Wide Open Agriculture is closing its German plant and pivoting to contract manufacturing in Asia to cut costs and scale lupin ingredient production efficiently under new CEO Craig Swan.

Navigator Global Investments has finalised its US$190 million acquisition of a diversified portfolio from Stable Asset Management, establishing a strategic partnership to manage the new assets and expanding its alternative investment footprint.

North Stawell Minerals (ASX:NSM) has expanded its gold footprint north of the Stawell Gold Mine, defining an 800-metre gold trend at Darlington and confirming significant mineralisation at Caledonia through re-split air core drilling assays.

Tasmea has completed its acquisition of Maxim Group, significantly expanding its electrical services footprint and positioning the segment to contribute more than half of FY27 earnings guidance.

Cyclopharm Limited delivered a record $17.1 million in revenue for 1H FY26, driven by a 73% surge in US Technegas® sales. However, delays in clinical guideline publication have pushed the short-term US installation target beyond 2026, while medium-term ambitions remain intact.

Telix Pharmaceuticals has gained FDA alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, setting the stage for U.S. enrolment pending regulatory approval.

BCAL Diagnostics has acquired a 10.2% stake in Genetic Signatures for $1.39 million, aiming to merge early cancer detection with infectious disease diagnostics and expand its international footprint.

Stelar Metals has uncovered new tungsten mineralisation zones at its Hill of Leaders project in the Northern Territory, setting the stage for imminent assay results and drilling campaigns.